Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99m Tc-peptide-Z HER2:342

Volume: 42, Issue: 6, Pages: 541 - 546
Published: Jun 1, 2015
Abstract
Patients with human epidermal growth factor receptor 2 (HER2)-positive cancer are candidates for treatment with the anti-HER2 antibody trastuzumab. How to systemically assess tumor HER2 expression and identifying appropriate use of anti-HER2 therapies by noninvasive imaging in vivo is an urgent issue. The purpose of this study was to evaluate SPECT imaging of 99mTc-Gly-(D)Ala-Gly-Gly-ZHER2:342 (99mTc-peptide-ZHER2:342) for monitoring therapeutic...
Paper Details
Title
Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99m Tc-peptide-Z HER2:342
Published Date
Jun 1, 2015
Volume
42
Issue
6
Pages
541 - 546
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.